Hemolytic-uremic syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 8: Line 8:
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*In children less than 5 years of age, the incidence of HUS is approximately 6 per 100,000.<ref name="pmid27723152">{{cite journal |vauthors=Karpman D, Loos S, Tati R, Arvidsson I |title=Haemolytic uraemic syndrome |journal=J. Intern. Med. |volume=281 |issue=2 |pages=123–148 |date=February 2017 |pmid=27723152 |doi=10.1111/joim.12546 |url=}}</ref>
*In children less than 5 years of age, the incidence of HUS is approximately 8.5 per 100,000.<ref name="pmid27723152">{{cite journal |vauthors=Karpman D, Loos S, Tati R, Arvidsson I |title=Haemolytic uraemic syndrome |journal=J. Intern. Med. |volume=281 |issue=2 |pages=123–148 |date=February 2017 |pmid=27723152 |doi=10.1111/joim.12546 |url=}}</ref>
*In 2016, the incidence of HUS was estimated to be 2 cases per 100,000 individuals, worldwide.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref>
*In 2016, the incidence of HUS was estimated to be 2 cases per 100,000 individuals, worldwide.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref>



Revision as of 15:39, 1 August 2018

Hemolytic-uremic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic-uremic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic-uremic syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic-uremic syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic-uremic syndrome epidemiology and demographics

CDC on Hemolytic-uremic syndrome epidemiology and demographics

Hemolytic-uremic syndrome epidemiology and demographics in the news

Blogs on Hemolytic-uremic syndrome epidemiology and demographics

Directions to Hospitals Treating Hemolytic-uremic syndrome

Risk calculators and risk factors for Hemolytic-uremic syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

Epidemiology and Demographics

Incidence

  • In children less than 5 years of age, the incidence of HUS is approximately 8.5 per 100,000.[1]
  • In 2016, the incidence of HUS was estimated to be 2 cases per 100,000 individuals, worldwide.[2]

Mortality rate

  • In 2017, the mortality of hemolytic uremic syndrome (HUS) is estimated to approximately 10% .[3]

Age

  • Patients of all age groups may develop hemolytic uremic syndrome (HUS).
  • The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.[2]
  • HUS commonly affects individuals younger 5 older than [number of years] years of age.[2]

Race

  • HUS usually affects individuals of the White race (82%).[4]

Gender

  • HUS affects female more than male. Approximately 59% of affected individuals are female.[4]

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

References

  1. Karpman D, Loos S, Tati R, Arvidsson I (February 2017). "Haemolytic uraemic syndrome". J. Intern. Med. 281 (2): 123–148. doi:10.1111/joim.12546. PMID 27723152.
  2. 2.0 2.1 2.2 Karpman, Diana; Loos, Sebastian; Tati, Ramesh; Arvidsson, Ida (2017). "Haemolytic uraemic syndrome". Journal of Internal Medicine. 281 (2): 123–148. doi:10.1111/joim.12546. ISSN 0954-6820.
  3. Gregory Hall, Shinichiro Kurosawa & Deborah J. Stearns-Kurosawa (2017). "Shiga Toxin Therapeutics: Beyond Neutralization". Toxins. 9 (9). doi:10.3390/toxins9090291. PMID 28925976. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 Deirdra R. Terrell, Sara K. Vesely, Johanna A. Kremer Hovinga, Bernhard Lammle & James N. George (2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". American journal of hematology. 85 (11): 844–847. doi:10.1002/ajh.21833. PMID 20799358. Unknown parameter |month= ignored (help)

Template:WH Template:WS